Other OTC - Delayed Quote • USD
CSL Limited (CMXHF)
At close: April 18 at 12:05 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul F. McKenzie Ph.D. | MD, CEO & Executive Director | 2.75M | -- | 1966 |
| Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 2.05M | -- | 1965 |
| Mr. Mark Dehring | Head of Investor Relations | -- | -- | -- |
| Mr. Gregory Boss B.S., BS(Hons), J.D. | Executive VP of Legal & General Counsel | 1.1M | -- | 1961 |
| Christina Hickie | Senior Manager of Communications | -- | -- | -- |
| Ms. Roanne Parry | Chief Human Resources Officer | -- | -- | -- |
| Dr. Karen Etchberger | Executive Vice President of Quality & Business Services | 1.03M | -- | 1958 |
| Ms. Jemimah Brennan | Head of Communications - Asia Pacific | -- | -- | -- |
| Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. | Senior Vice President of Research | -- | -- | 1962 |
| Dr. William Mezzanotte M.D., M.P.H. | Executive VP & Head of Research and Development | 1.46M | -- | 1959 |
CSL Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 32,065
Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Corporate Governance
CSL Limited’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 1; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 11, 2024Ex-Dividend Date
- Apr 04, 2014Dividend Date
Upcoming Events
Upcoming Events Information Not Available
Related Tickers
GNMSF Genmab A/S
284.55
-2.01%
SBMFF Sino Biopharmaceutical Limited
0.3150
-9.83%
GMAB Genmab A/S
28.70
+1.31%
ADMA ADMA Biologics, Inc.
6.27
+1.13%
RARE Ultragenyx Pharmaceutical Inc.
42.37
-2.33%
EDIT Editas Medicine, Inc.
5.49
-1.08%
MRNS Marinus Pharmaceuticals, Inc.
1.3800
-2.13%
NTLA Intellia Therapeutics, Inc.
21.57
+1.17%
REGN Regeneron Pharmaceuticals, Inc.
896.82
+0.32%
GERN Geron Corporation
3.6900
-1.07%